ADA 2020: Spotlight on Closed-Loop Insulin Delivery Systems, CGM for Type 2s

article image
ARTICLE SUMMARY:

Automated insulin delivery systems were a highlight of this year’s (virtual) ADA meeting, with presentations on new devices from Medtronic, Tandem Diabetes Care, Insulet, Beta Bionics, and Eli Lilly, all vying for a top spot in this fast-evolving space. Industry analysts opine on their commercial prospects as well as Dexcom and Abbott’s efforts to expand CGM to the type 2 diabetes population.

The 2020 American Diabetes Association (ADA) meeting was held remotely in mid-June and thus was more subdued than in previous years; however, some important device studies were presented, particularly in the areas of next-gen automated insulin delivery (AID) systems and continuous glucose monitoring (CGM).

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.


Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite

Questions?

We're here to help! Please contact us at: